Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 236

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 236
---
715
of federal Research and Development (R&D) tax credits. These can be carried forward 20 years to offset future federal income tax.
These begin to expire in 2037. Additionally, the Company has $80,000 of state R&D tax credits which can be carried forward seven years.
These begin to expire in 2030.

Note 11 – Quarterly Financial Data (Unaudited and Restated)

The Company is providing restated quarterly unaudited consolidated financial information as of September 30, 2023 in the table below. See Note 2, Restatement of Previously Issued Consolidated Financial Statements, for further background concerning the events preceding the restatement of financial information in this Comprehensive Form 10-K/A.

The restated consolidated balance sheet line items for the third fiscal quarter of 2023 are as follows:

Schedule of Quarterly Financial Data

|                                |     | As Reported | September 30, 2023 |   |     | Adjustments | September 30, 2023 |   |     | Restated | September 30, 2023 |   |
|:-------------------------------|:----|:------------|-------------------:|:--|:----|:------------|-------------------:|:--|:----|:---------|-------------------:|:--|
| Additional paid in capital (1) |     |             |         19,456,841 |   |     |             |          9,945,692 |   |     |          |         29,402,533 |   |
| Accumulated deficit            |     |             |        (13,847,112 | ) |     |             |         (9,945,692 | ) |     |          |        (23,792,804 | ) |

| (1) | The                                                                                       
 Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated 
 balance sheet for the period ended September 30, 2023 with an increase to additional paid 
 in capital of $140 and an offsetting adjustment to the carrying value of common stock.    |

The adjustments did not have an effect on the consolidated
statement of operations or cash flows for the three fiscal quarters of 2023.

The Company has included its restated quarterly unaudited
consolidated financial information for the interim periods ended March 31, 2023 and June 30, 2023 within Form 10-Q/A for the period ended
March 31